RenovoRx Pfcf Ratio from 2010 to 2024

RNXT Stock  USD 1.27  0.01  0.79%   
RenovoRx PFCF Ratio yearly trend continues to be comparatively stable with very little volatility. PFCF Ratio will likely drop to -2.41 in 2024. From the period from 2010 to 2024, RenovoRx PFCF Ratio quarterly data regression had mean square error of  20.29 and mean deviation of  5.90. View All Fundamentals
 
PFCF Ratio  
First Reported
2010-12-31
Previous Quarter
(2.30)
Current Value
(2.41)
Quarterly Volatility
7.00122807
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check RenovoRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RenovoRx's main balance sheet or income statement drivers, such as Net Interest Income of 116.5 K, Interest Income of 64.3 K or Depreciation And Amortization of 5.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. RenovoRx financial statements analysis is a perfect complement when working with RenovoRx Valuation or Volatility modules.
  
Check out the analysis of RenovoRx Correlation against competitors.
For more information on how to buy RenovoRx Stock please use our How to Invest in RenovoRx guide.

Latest RenovoRx's Pfcf Ratio Growth Pattern

Below is the plot of the Pfcf Ratio of RenovoRx over the last few years. It is RenovoRx's PFCF Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in RenovoRx's overall financial position and show how it may be relating to other accounts over time.
Pfcf Ratio10 Years Trend
Slightly volatile
   Pfcf Ratio   
       Timeline  

RenovoRx Pfcf Ratio Regression Statistics

Arithmetic Mean(14.66)
Coefficient Of Variation(47.75)
Mean Deviation5.90
Median(18.77)
Standard Deviation7.00
Sample Variance49.02
Range16.4744
R-Value0.78
Mean Square Error20.29
R-Squared0.62
Significance0.0005
Slope1.23
Total Sum of Squares686.24

RenovoRx Pfcf Ratio History

2023 -2.3
2022 -2.41
2021 -7.29
2020 -17.82

About RenovoRx Financial Statements

RenovoRx shareholders use historical fundamental indicators, such as Pfcf Ratio, to determine how well the company is positioned to perform in the future. Although RenovoRx investors may analyze each financial statement separately, they are all interrelated. The changes in RenovoRx's assets and liabilities, for example, are also reflected in the revenues and expenses on on RenovoRx's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
PFCF Ratio(2.30)(2.41)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for RenovoRx Stock Analysis

When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.